- Revolution Medicines’ potential breakthrough pancreatic cancer drug succeeds in late-stage trial CNBC
- RevMed’s Cancer Drug Nearly Doubles Overall Survival in Pivotal Study Bloomberg.com
- Revolution’s much-hyped RAS inhibitor hits key survival goals in phase 3 pancreatic cancer trial Fierce Biotech
- Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill statnews.com
- In the latest published clinical trial data, the oral anti-cancer drug developed by Revolution Medicines showed significant efficacy, successfully extending the survival of patients with advanced cancer. Bitget
Leave a Reply